Caribou Biosciences to halt CAR-T programs, explore sale
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- S&P 500, Nasdaq retreat from record highs as yields and oil climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
Caribou Biosciences to Evaluate Strategic Alternatives
October 6, 2026 4:05 PM EDT-- Company to evaluate strategic alternatives to maximize stockholder value --
-- Caribou plans to discontinue vispa-cel and CB-011 allogeneic CAR-T cell therapy programs --
-- Cash, cash equivalents, and marketable securities of $113.8 million as of June 30, 2026 --
BERKELEY, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it is exploring strategic alternatives to maximize stockholder value and plans to discontinue further development activities for its two... More



